Blavatnik Biomedical Accelerator
Offers Harvard biomedical innovators pilot support for early proof-of-concept delivery.
The Blavatnik Biomedical Accelerator (BBA) is Harvard's principal internal proof-of-concept funding mechanism for early-stage biomedical research, administered by the Harvard Office of Technology Development (OTD). The BBA was endowed with seed funding from the Blavatnik Family Foundation and is now operated entirely by Harvard OTD. It funds translation of early-stage research across four defined …
Proof-of-concept development of early-stage Harvard biomedical research across cell and gene therapy, infectious and inflammatory diseases, platform technologies, medical devices, therapeutics, diagnostics, drug delivery, and enabling technologies for drug discovery.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline